Gene therapy with plasmids encoding IFN-β or IFN-α14 confers long-term resistance to HIV-1 in humanized mice
Open Access
- 6 October 2016
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (48) , 78412-78420
Abstract
Gene therapy with plasmids encoding IFN-β or IFN-α14 confers long-term resistance to HIV-1 in humanized miceKeywords
This publication has 34 references indexed in Scilit:
- Interferon-α Is the Primary Plasma Type-I IFN in HIV-1 Infection and Correlates with Immune Activation and Disease MarkersPLOS ONE, 2013
- Long-Term Engraftment of Human Natural T Regulatory Cells in NOD/SCID IL2rγcnull Mice by Expression of Human IL-2PLOS ONE, 2012
- Interferon-alpha Subtype 11 Activates NK Cells and Enables Control of Retroviral InfectionPLOS Pathogens, 2012
- HIV Restriction Factors and Mechanisms of EvasionCold Spring Harbor Perspectives in Medicine, 2012
- Structural variants of IFNα preferentially promote antiviral functionsBlood, 2011
- Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa‐2a in HIV‐1–Monoinfected Participants: A Phase II Clinical TrialThe Journal of Infectious Diseases, 2010
- Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized miceProceedings of the National Academy of Sciences, 2009
- Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeysJournal of Clinical Investigation, 2009
- Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN responseJournal of Clinical Investigation, 2009
- Hydrodynamic Gene Delivery: Its Principles and ApplicationsMolecular Therapy, 2007